Carbidopa is useful in the management of Parkinson's disease because it is an:

A. Carbidopa is not a dopamine receptor agonist. It does not directly stimulate D2 receptors in the central nervous system, so it cannot by itself improve Parkinsonian motor symptoms. Its role is supportive, enhancing the effectiveness of levodopa rather than acting as a substitute for dopamine receptor stimulation. B. Carbidopa is not a D2 antagonist. Blocking dopamine receptors would worsen Parkinson symptoms, as Parkinson disease is caused by dopamine deficiency in the basal ganglia. Therefore, a D2 antagonist would be counterproductive. C. Carbidopa is a peripheral decarboxylase inhibitor. It inhibits the enzyme aromatic L-amino acid decarboxylase (AADC) outside the central nervous system. This enzyme normally converts levodopa to dopamine in the periphery, which reduces the amount of levodopa available to the brain and causes peripheral side effects such as nausea, vomiting, and hypotension. By inhibiting peripheral conversion, carbidopa increases levodopa delivery to the brain, allowing it to cross the blood-brain barrier and be converted to dopamine where it is needed. It also reduces the peripheral adverse effects of levodopa and enables lower levodopa doses while maintaining therapeutic effect. D. Carbidopa does not cross the blood-brain barrier, so it does not inhibit decarboxylase in the CNS. Its action is strictly peripheral, which is why it is paired with levodopa to maximize levodopa availability in the brain without increasing central toxicity